Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders
NCT06549114Phase 2Completed
- Sponsor
- Pharming Group
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leniolisib in primary immunodeficiency disorder (PID), sponsored by Pharming Group. Primary endpoint: Number of Participants with Treatment-emergent adverse events, Serious Adverse Events, and Adverse Events at 20 weeks. Started Oct 2024; status: completed.
02
Drugs
leniolisib
03
Conditions
primary immunodeficiency disorder (PID)
Beyond the preview
Go deeper on NCT06549114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549114.